Anti-CD220/INSR Polyclonal Antibody from ProteoGenix; catalogue ARO-A22170; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Anti-CD220/INSR Polyclonal Antibody: A Versatile Tool for Studying Insulin Receptor Signaling
The Anti-CD220/INSR Polyclonal Antibody is a highly specific and reliable tool for studying insulin receptor signaling. This antibody is produced using advanced biotechnology techniques, ensuring high purity and quality for optimal experimental results.
The insulin receptor, also known as CD220 or INSR, is a transmembrane receptor that plays a crucial role in regulating glucose metabolism. Upon binding with insulin, the receptor undergoes a conformational change, leading to the activation of downstream signaling pathways. The Anti-CD220/INSR Polyclonal Antibody specifically targets the extracellular domain of the insulin receptor, allowing for the detection and analysis of its activation and signaling.
The Anti-CD220/INSR Polyclonal Antibody has a wide range of applications in the field of biotechnology and biomedical research. It is commonly used in studies related to diabetes, obesity, and other metabolic disorders. This antibody is also essential in investigating the mechanisms of insulin resistance and its role in various diseases.
The Anti-CD220/INSR Polyclonal Antibody has been extensively used in various experimental settings, including Western blotting, immunoprecipitation, and immunofluorescence. It has been shown to effectively detect and quantify insulin receptor expression and activation in different cell types and tissues. This antibody has also been used in functional assays to study the downstream signaling pathways of the insulin receptor.
Target Research Keywords:
– Insulin receptor signaling
– Insulin resistance
– Metabolic disorders
– Diabetes
– Obesity
– Western blotting
– Immunoprecipitation
– Immunofluorescence
– Downstream signaling pathways
Conclusion:
In summary, the Anti-CD220/INSR Polyclonal Antibody is a valuable tool for studying the critical role of the insulin receptor in various biological processes. Its high specificity and sensitivity make it an ideal choice for researchers and scientists working in the field of biotechnology and metabolic disorders. Trust in the quality and reliability of this antibody for your research needs.
ProteoGenix catalogue number ARO-A22170. For research use only.
Target: Insulin receptor; IR; 2.7.10.1; CD220; Insulin receptor subunit alpha; Insulin receptor subunit beta; Insr; Clonality: Polyclonal Antibody; Applications: ELISA, IHC.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | IHC |
|---|---|---|---|---|---|---|---|---|---|
| Insulin receptor; IR; 2.7.10.1; CD220; Insulin receptor subunit alpha; Insulin receptor subunit beta; Insr |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
